13F Holdings
中文EN

OVID Ovid Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1636651 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-78.0%
TTM net income YoY-18.7%
TTM EPS YoY—
Revenue 3-yr CAGR69.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,700.3%
Net margin-2,971.3%
FCF margin—
EBITDA margin-4,694.6%

Returns

ROE-35.4%
ROA-30.1%
ROIC (approx.)-52.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets10.6%
Debt / equity0.00x
Current ratio11.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.34x
Accruals ratio10.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.25M$566,000$392,000$1.50M$208.38M
R&D expense$25.58M$36.77M$28.59M$24.62M$46.94M
SG&A expense$24.11M$25.68M$31.09M$32.43M$37.23M
Operating income-$42.44M-$61.88M-$59.28M-$55.55M$124.21M
Pretax income-$17.41M-$26.43M-$52.34M-$54.17M$124.16M
Income tax$0$0$0$0$1.33M
Net income-$17.41M-$26.43M-$52.34M-$54.17M$122.83M
EBITDA-$42.17M-$61.27M-$58.71M-$55.04M$124.45M
EPS (basic)——-0.74-0.771.78
EPS (diluted)——-0.74-0.771.76
Weighted avg. shares (diluted)——70.58M70.42M68.07M
Balance sheet
Cash & equivalents$13.15M$28.23M$28.97M$46.80M$189.73M
Short-term investments$56.48M$26.77M$78.79M$84.13M$0
Current assets$74.37M$55.94M$109.60M$131.38M$190.48M
PP&E, net$252,000$433,000$769,000$1.15M$242,757
Intangibles$0$100,000$200,000$222,100$164,092
Total assets$150.93M$92.17M$144.03M$155.27M$194.54M
Current liabilities$8.29M$10.52M$11.47M$6.99M$14.80M
Total liabilities$20.27M$23.94M$56.23M$22.99M$14.80M
Shareholders' equity$130.66M$68.23M$87.80M$132.27M$179.75M
Shares outstanding130.18M71.01M70.69M70.47M70.36M
Cash flow statement
Operating cash flow-$38.33M-$55.96M-$45.78M-$55.23M$118.61M
Capital expenditure$0$71,000$40,000$1.22M$184,008
Free cash flow-$38.33M-$56.03M-$45.82M-$56.45M$118.43M
Investing cash flow-$49.85M$54.59M-$2.58M-$87.88M-$1.82M
Financing cash flow$75.21M$622,000$30.54M$180,658$904,082
Depreciation & amortization$273,000$613,000$568,000$512,505$237,079
Stock-based compensation$4.81M$6.28M$7.29M$6.56M$5.05M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.